BioSpace News Archive

New technology poised to drastically reduce weight, complexity and cost of cameras while increasing functionality

The n-Lorem Foundation announced today it has received an initial pledge of $500,000 from Mark Lampert in support of the n-Lorem Foundation’s efforts to provide advanced, experimental RNA-targeted medicines free of charge for life to patients living with ultra-rare diseases

In response to the WHO classifying COVID-19 as a pandemic, ej4 is offering new training content to help clients inform their employees about what coronavirus is, and how they can take precautionary measures to prepare for a pandemic situation.

March 12, is World Kidney Day, and the National Kidney Foundation would like you to observe the occasion by dedicating one minute of your day to take the Kidney Risk Quiz.

VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Damian Braga has joined its Board of Directors.

Motus GI Holdings, Inc. announced that it is relocating its corporate headquarters from Fort Lauderdale, Fl. to Boston in Q2 2020.

McKesson Corporation (NYSE:MCK) today announced the final results of its offer to its stockholders to exchange their issued and outstanding shares of McKesson common stock for shares of PF2 SpinCo, Inc. (“SpinCo”) common stock owned by McKesson as part of its split-off of its interest in Change Healthcare LLC (“Change Healthcare”) and its agreement with Change Healthcare Inc. (NASDAQ:CHNG) (“Change”) to merge SpinCo with and into Change.

NeuExcell Therapeutics, Inc., an early-stage gene therapy company focusing on neurodegenerative diseases, today announced the publication of research demonstrating proof of principle for the company’s investigational gene therapy, which generated functional new neurons in animal models of Huntington’s disease (HD).

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, wishes to address a sharp reduction of its share price and subsequent brief trading halt of its shares occurred this morning.

Global and our affiliates have received numerous inquiries about whether or not people with Down syndrome are more at risk than typical people when it comes to exposure to the coronavirus disease (COVID-19)